Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Short-term Investments (2020 - 2023)

Cullinan Therapeutics has reported Short-term Investments over the past 4 years, most recently at $401.6 million for Q3 2023.

  • Quarterly results put Short-term Investments at $401.6 million for Q3 2023, up 20.49% from a year ago — trailing twelve months through Sep 2023 was $401.6 million (up 20.49% YoY), and the annual figure for FY2022 was $311.1 million, up 34.87%.
  • Short-term Investments for Q3 2023 was $401.6 million at Cullinan Therapeutics, up from $350.0 million in the prior quarter.
  • Over the last five years, Short-term Investments for CGEM hit a ceiling of $401.6 million in Q3 2023 and a floor of $42.0 million in Q4 2020.
  • Median Short-term Investments over the past 4 years was $248.1 million (2022), compared with a mean of $252.2 million.
  • Biggest five-year swings in Short-term Investments: skyrocketed 449.16% in 2021 and later grew 12.5% in 2023.
  • Cullinan Therapeutics' Short-term Investments stood at $42.0 million in 2020, then skyrocketed by 449.16% to $230.7 million in 2021, then surged by 34.87% to $311.1 million in 2022, then grew by 29.07% to $401.6 million in 2023.
  • The last three reported values for Short-term Investments were $401.6 million (Q3 2023), $350.0 million (Q2 2023), and $268.6 million (Q1 2023) per Business Quant data.